@ Evchen u. alle - Studie EZS hcg-Gabe

Hallo zusammen,

Evchen schrieb letztens:

-------

Hi Sunny,

Dr. Uher erklärte mir, daß kürzlich bei einem Kongreß über EZS eine Studie vorgestellt wurde, nach der die Einnistungswahrscheinlichkeit bei der vorherigen Gabe von Choragon (oder Pregnesin oder Predalon, ist alles dasselbe) signifikant ansteigt.

Und bei mir hat's jedenfalls auf Anhieb geklappt!

LG
Evchen (mit Tricka & Tracko, 27 W + 5T)

-------

Diese Studie finde ich höchst interessant. Gibt es hier irgend jemanden, der sie kennt? Oder vielleicht gerade im Kontakt mit Dr. Uher steht u. einmal nachfragen könnte? Oder zumindest, warum hcg bei downregulierten Frauen Erfolg hat? (normalerweise stimuliert das hcg den Gelbkörper... aber der Gelbkörper ist doch gar nicht vorhanden).

Das wäre sicherlich für alle hier höchst interessant...

Liebe Grüße
SunnySunshine

... endlich was gefunden ...

http://www.ncbi.nlm.nih.gov/entrez/query.f…t_uids=12930575

Reprod Biomed Online. 2003 Jul-Aug;7(1):59-64. Related Articles, Links

Luteinizing hormone affects uterine receptivity independently of ovarian function.

Tesarik J, Hazout A, Mendoza C.

MAR&Gen, Molecular Assisted Reproduction and Genetics, Gracia 36, 18002 Granada, Spain. cmendoza@ugr.es

Previous studies have suggested that LH, in addition to its well-known effects on the ovary, may exert direct effects on the uterus. This study evaluated the effects of mid-cycle administration of human chorionic gonadotrophin (HCG), which signals through the LH receptor, on endometrial thickness and uterine receptivity in two groups of women lacking ovarian activity and receiving embryos from an oocyte donation programme. Patients in one group still had ovulatory cycles, but their ovarian function was suppressed by pituitary down-regulation with a gonadotrophin-releasing hormone (GnRH) agonist in the embryo transfer cycle, resulting in low endogenous LH concentrations. Patients in the other group were menopausal women whose pituitary function was not down-regulated in the embryo transfer cycle and whose endogenous LH concentrations were thus high. Patients in each of the two groups were randomized into two subgroups. Patients in one subgroup were given 5000 IU of HCG 2 days before oocyte recovery in the corresponding donor. Patients in the other subgroup received placebo at the same time. Oocytes from each donor were randomly distributed between one patient from the HCG subgroup and one patient from the placebo subgroup in each patient group. Endometrial growth and secretory transformation were stimulated by sequential treatment with oestradiol valerate and progesterone. In women with low endogenous LH receiving placebo, endometrial thickness stopped increasing at the beginning of secretory transformation. Mid-cycle HCG administration resulted in a continuous increase in endometrial thickness through this period, improved the implantation rate after embryo transfer in these women (30.6 versus 20.7%) and augmented the number of multiple pregnancies. No similar stagnation of endometrial thickness and no effects of mid-cycle HCG administration on endometrial thickness, the implantation rate and the number of multiple pregnancies were found in women with high endogenous LH. It is concluded that endometrial maturation is disturbed in women with low endogenous LH but can be rescued by mid-cycle stimulation of LH receptor with exogenous HCG in the absence of ovarian activity.

PMID: 12930575 [PubMed - indexed for MEDLINE]